Side effects of tirzepatide (Mounjaro): what you need to know
Short answer: The most common side effects of tirzepatide are nausea, diarrhoea and vomiting. These usually occur at the start of treatment, are temporary and subside after 4 to 8 weeks thanks to the gradual titration schedule.
Mounjaro® (tirzepatide) is rapidly gaining ground as one of the most effective weight-loss medicines currently available on the market. The medicine acts on two receptors simultaneously: the GLP-1 receptor and the GIP receptor, ensuring greater weight loss than traditional GLP-1 agents. However, it is precisely this dual action that raises legitimate questions about the side effects of tirzepatide. What can you expect? How long do the side effects last? And when should you contact your doctor? You can find the answers in this blog.
What are the most common side effects of Mounjaro?
The most common side effects of Mounjaro are gastrointestinal problems: nausea, diarrhoea, vomiting, abdominal pain and constipation. These occur in a significant proportion of users, particularly in the first few weeks or following a dose increase. A reduced appetite is technically also a side effect, but is seen by most users as a welcome one.
The SURMOUNT-1 study shows that nausea occurred in 28 to 39 per cent of participants, depending on the dose, whilst most cases were described as mild to moderate. Diarrhoea occurred in 17 to 23 per cent of participants. In most cases, these symptoms resolved on their own as the body adjusted to the medication.
In addition, a slight increase in heart rate (3 to 5 beats per minute) has been reported. This is not usually clinically relevant, but warrants attention in people with heart conditions.
How long do the side effects of Mounjaro last?
Gastrointestinal side effects subside in most users after four to eight weeks. The dosing schedule for Mounjaro is specifically designed with this in mind: treatment starts with 2.5 mg per week and is increased every four weeks to 5, 7.5, 10, 12.5 and finally a maximum of 15 mg per week, as described in Farmacotherapeutisch Kompas.
Safety data from a phase 3 study show that most side effects occurred during the first one to two dose increases and then subsided significantly. The highest peak in the number of complaints is therefore at the start of treatment, not at the end.
Are there any serious side effects associated with tirzepatide?
Serious side effects do occur, but they are rare. The most relevant are acute pancreatitis, gallstones (cholelithiasis) and kidney problems resulting from dehydration due to persistent vomiting or diarrhoea. If you experience persistent severe abdominal pain radiating into your back, you should always contact a doctor.
In animal studies, thyroid cancer has been observed, a finding that has also been reported with other GLP-1 agonists. This has not yet been demonstrated in humans, but tirzepatide is contraindicated in individuals with a personal or family history of medullary thyroid cancer. The same applies to MEN2 (multiple endocrine neoplasia type 2).
Real-world studies show that serious side effects are rare when the medicine is used correctly and with proper guidance. A thorough review of the patient’s medical history at the start of treatment is therefore essential.
How does Mounjaro differ from Ozempic and Wegovy in terms of side effects?
Tirzepatide acts on two receptors, GLP-1 and GIP, which means it is both more potent and qualitatively different from semaglutide (Ozempic/Wegovy). The side effect profile is largely comparable, but at higher doses, gastrointestinal discomfort may be slightly more intense due to the stronger effect on gastric emptying.
A head-to-head study shows that tirzepatide resulted in significantly greater weight loss than semaglutide 1 mg per week in people with type 2 diabetes, with a comparable safety profile. Read more about the difference between Mounjaro and Ozempic, or see the side effects of Ozempic for further information.
The table below summarises the key differences:
What can you do to reduce the side effects of Mounjaro?
The most effective way to limit side effects is to change your eating habits. Small, low-fat meals significantly reduce the risk of nausea. Avoid large portions, alcohol and high-fat or high-sugar foods, especially in the first few weeks after a dose increase. Good hydration is essential, precisely because diarrhoea and vomiting can lead to dehydration.
Read more about nutrition whilst using GLP-1 for specific tips tailored to the use of Mounjaro. Some users experience fewer side effects if they take the injection just before bedtime, so that the first few hours after the injection coincide with the night. The timing and choice of food together make a noticeable difference, especially in the first four weeks of treatment. Goodweigh actively monitors each dose increase and adjusts the titration plan if the side effects persist.
When should you stop taking Mounjaro due to side effects?
Stop using the medication and contact a doctor immediately if you experience severe, persistent abdominal pain, especially if it radiates into your back. This may indicate acute pancreatitis. Jaundice or dark urine may indicate liver problems or gallstones. Severe dehydration can be recognised by dizziness, dark urine and infrequent urination.
Mild discomfort at the start is normal and to be expected. There is a difference between temporary discomfort when the dose is increased and symptoms that persist or worsen. If in doubt, contact your doctor. Medical guidance from Goodweigh is available throughout your treatment.
Side effects of Mounjaro can be managed with the right guidance
Most side effects of tirzepatide are mild, temporary and subside the longer you use the medicine. The titration schedule, combined with changes in eating habits, makes the treatment well tolerated by most people. The SURMOUNT-2 trial shows that even with long-term use at higher doses, the side effect profile remains acceptable.
Would you like to start Mounjaro safely under medical supervision? Through Goodweigh, you’ll undergo an online consultation, receive a personalised dosing schedule, and a team of doctors will be on hand if you have any questions or concerns. Discreetly delivered to your door, fully arranged online.
Referencer
- Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., Wharton, S., Connery, L., Alves, B., ... & Wadden, T.A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Frías, J.P., Davies, M.J., Rosenstock, J., Pérez Manghi, F.C., Fernández Landó, L., Bergman, B.K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503–515. https://pubmed.ncbi.nlm.nih.gov/34170647/
- Garvey, W.T., Frias, J.P., Jastreboff, A.M., le Roux, C.W., Sattar, N., Aizenberg, D., ... & SURMOUNT-2 Investigators. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet, 402(10402), 613–626. https://pubmed.ncbi.nlm.nih.gov/37385275/
- Rosenstock, J., Wysham, C., Frías, J.P., Kaneko, S., Lee, C.J., Fernández Landó, L., ... & SURPASS-1 Investigators. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet, 398(10295), 143–155. https://pubmed.ncbi.nlm.nih.gov/34186022/
- Thomsen, R.W., Pedersen, L., Hasvold, P., Sandbæk, A., & García Rodríguez, L.A. (2025). Real-world evidence on GLP-1RA-based weight-loss therapies. Diabetes, Obesity and Metabolism. https://pubmed.ncbi.nlm.nih.gov/40196933/
- Farmacotherapeutisch Kompas. (2024). Tirzepatide. Zorginstituut Nederland. https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/t/tirzepatide
Your final weight-loss programme
Transform your life with the Goodweigh weight loss programme, designed for lasting success.
.avif)

